The intestinal stem cell signature identifies colorectal cancer stem cells and predicts disease relapse.

A frequent complication in colorectal cancer (CRC) is regeneration of the tumor after therapy. Here, we report that a gene signature specific for adult intestinal stem cells (ISCs) predicts disease relapse in CRC patients. ISCs are marked by high expression of the EphB2 receptor, which becomes gradually silenced as cells differentiate. Using EphB2 and the ISC marker Lgr5, we have FACS-purified and profiled mouse ISCs, crypt proliferative progenitors, and late transient amplifying cells to define a gene program specific for normal ISCs. Furthermore, we discovered that ISC-specific genes identify a stem-like cell population positioned at the bottom of tumor structures reminiscent of crypts. EphB2 sorted ISC-like tumor cells display robust tumor-initiating capacity in immunodeficient mice as well as long-term self-renewal potential. Taken together, our data suggest that the ISC program defines a cancer stem cell niche within colorectal tumors and plays a central role in CRC relapse.

[1]  Jiafu Ji,et al.  Reduced expression of EphB2 that parallels invasion and metastasis in colorectal tumours. , 2006, Carcinogenesis.

[2]  N. Zeps,et al.  Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  R. Knuechel,et al.  Variable β-catenin expression in colorectal cancers indicates tumor progression driven by the tumor environment , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[4]  E. Giovannucci,et al.  Cyclooxygenase-2 Expression Is an Independent Predictor of Poor Prognosis in Colon Cancer , 2008, Clinical Cancer Research.

[5]  J. Dick,et al.  A human colon cancer cell capable of initiating tumour growth in immunodeficient mice , 2007, Nature.

[6]  James J. Chen,et al.  Kernel estimation for adjusted p , 2007, Comput. Stat. Data Anal..

[7]  K. Sugihara,et al.  Cyclooxygenase-2 Expression , 2004, Clinical Cancer Research.

[8]  T. Pawson,et al.  EphB receptor activity suppresses colorectal cancer progression , 2005, Nature.

[9]  G. Smyth,et al.  ELDA: extreme limiting dilution analysis for comparing depleted and enriched populations in stem cell and other assays. , 2009, Journal of immunological methods.

[10]  G. Stassi,et al.  The AC133 epitope, but not the CD133 protein, is lost upon cancer stem cell differentiation. , 2010, Cancer research.

[11]  G. Glinsky,et al.  Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer. , 2005, The Journal of clinical investigation.

[12]  Stuart H. Orkin,et al.  A Myc Network Accounts for Similarities between Embryonic Stem and Cancer Cell Transcription Programs , 2010, Cell.

[13]  L. Terracciano,et al.  High frequency of tumor‐infiltrating FOXP3+ regulatory T cells predicts improved survival in mismatch repair‐proficient colorectal cancer patients , 2010, International journal of cancer.

[14]  Michael F. Clarke,et al.  Phenotypic characterization of human colorectal cancer stem cells , 2007, Proceedings of the National Academy of Sciences.

[15]  L. Ricci-Vitiani,et al.  Identification and expansion of human colon-cancer-initiating cells , 2007, Nature.

[16]  Paul Polakis,et al.  EphB2 as a Therapeutic Antibody Drug Target for the Treatment of Colorectal Cancer , 2004, Cancer Research.

[17]  A. Regev,et al.  An embryonic stem cell–like gene expression signature in poorly differentiated aggressive human tumors , 2008, Nature Genetics.

[18]  Hans Clevers,et al.  Transcription Factor Achaete Scute-Like 2 Controls Intestinal Stem Cell Fate , 2009, Cell.

[19]  H. Clevers,et al.  The Intestinal Wnt/TCF Signature. , 2007, Gastroenterology.

[20]  K. Chayama,et al.  Clinical Significance of Angiogenic Factor Expression at the Deepest Invasive Site of Advanced Colorectal Carcinoma , 2002, Oncology.

[21]  P. Galle,et al.  Effect of Chemokine Receptors CXCR4 and CCR7 on the Metastatic Behavior of Human Colorectal Cancer , 2005, Clinical Cancer Research.

[22]  Tony Pawson,et al.  β-Catenin and TCF Mediate Cell Positioning in the Intestinal Epithelium by Controlling the Expression of EphB/EphrinB , 2002, Cell.

[23]  Louis Vermeulen,et al.  Wnt activity defines colon cancer stem cells and is regulated by the microenvironment , 2010, Nature Cell Biology.

[24]  J. Gordon,et al.  Examining the Role of Paneth Cells in the Small Intestine by Lineage Ablation in Transgenic Mice* , 1997, The Journal of Biological Chemistry.

[25]  Hans Clevers,et al.  Lgr5(+ve) stem cells drive self-renewal in the stomach and build long-lived gastric units in vitro. , 2010, Cell stem cell.

[26]  Suet Yi Leung,et al.  Gene expression patterns of human colon tops and basal crypts and BMP antagonists as intestinal stem cell niche factors , 2007, Proceedings of the National Academy of Sciences.

[27]  H. Clevers,et al.  Identification of stem cells in small intestine and colon by marker gene Lgr5 , 2007, Nature.

[28]  J. Lloreta,et al.  EphB–ephrin-B interactions suppress colorectal cancer progression by compartmentalizing tumor cells , 2007, Nature Genetics.

[29]  E. Verwiel,et al.  Deletion of the WNT target and cancer stem cell marker CD44 in Apc(Min/+) mice attenuates intestinal tumorigenesis. , 2008, Cancer research.

[30]  Ian A. White,et al.  CD133 expression is not restricted to stem cells, and both CD133+ and CD133- metastatic colon cancer cells initiate tumors. , 2008, The Journal of clinical investigation.

[31]  M. Todaro,et al.  Single-cell cloning of colon cancer stem cells reveals a multi-lineage differentiation capacity , 2008, Proceedings of the National Academy of Sciences.

[32]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[33]  A. Reeve,et al.  Reduced expression of a gene proliferation signature is associated with enhanced malignancy in colon cancer , 2008, British Journal of Cancer.

[34]  Y. Benjamini,et al.  THE CONTROL OF THE FALSE DISCOVERY RATE IN MULTIPLE TESTING UNDER DEPENDENCY , 2001 .

[35]  H. Clevers,et al.  Prominin-1/CD133 marks stem cells and early progenitors in mouse small intestine. , 2009, Gastroenterology.

[36]  Hans Clevers,et al.  Crypt stem cells as the cells-of-origin of intestinal cancer , 2009, Nature.

[37]  Y. Collan,et al.  VEGF-1 expression in colorectal cancer is associated with disease localization, stage, and long-term disease-specific survival. , 2008, Anticancer research.

[38]  H. Grabsch,et al.  EphB2 is a Prognostic Factor in Colorectal Cancer , 2005, Clinical Cancer Research.

[39]  H. Clevers,et al.  Single Lgr5 stem cells build crypt–villus structures in vitro without a mesenchymal niche , 2009, Nature.

[40]  Hiroya Takeuchi,et al.  Chemokine receptor CXCR4 expression in colorectal cancer patients increases the risk for recurrence and for poor survival. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  P. Pelicci,et al.  Biological and Molecular Heterogeneity of Breast Cancers Correlates with Their Cancer Stem Cell Content , 2010, Cell.

[42]  T. Yeatman,et al.  Experimentally derived metastasis gene expression profile predicts recurrence and death in patients with colon cancer. , 2010, Gastroenterology.

[43]  T. Ørntoft,et al.  Metastasis-Associated Gene Expression Changes Predict Poor Outcomes in Patients with Dukes Stage B and C Colorectal Cancer , 2009, Clinical Cancer Research.